Drugs / E. coli Nissle 1917
E. coli Nissle 1917
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01013259 | Feb → Sep 2009 | allergic rhinitis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT04969679 Comparator | Mar 2018 → Jun 2020 | ulcerative colitis | Kangbuk Samsung Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02726295 Comparator | Sep 2016 → Oct 2017 | constipation disorder | Keimyung University Dongsan Medical Center | Completed | No outcome recorded |
| — | NCT03800147 Comparator | Jan → Sep 2019 | escherichia coli infection | University of Zurich | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E.coli Nissle 1917 | “E.coli Nissle 1917 (Mutaflor®) is equivalent to mesalazine in preventing disease relapse in ulcerative colitis.” NCT04969679 ↗ |
| Known as | EcN | “Escherichia coli Nissle 1917 (EcN) is equivalent to mesalazine for preventing disease relapse” PMID 36068716 ↗ Mar 2022 |
| Known as | Escherichia coli Nissle 1917 | “Escherichia coli Nissle 1917 (EcN) is equivalent to mesalazine for preventing disease relapse” PMID 36068716 ↗ Mar 2022 |
| Known as | Mutaflor | “E.coli Nissle 1917 (Mutaflor®) is equivalent to mesalazine in preventing disease relapse in ulcerative colitis.” NCT04969679 ↗2“E. coli Nissle 1917 (Mutaflor®) has been used for chronic constipation” NCT02726295 ↗ |
| Modality | Other / unclassified | “the non-pathogenic bacteria E. coli Nissle” NCT03800147 ↗ |
| Route | Oral | “Take 1 capsule per day in the morning from the first day to the fourth day and take 2 capsules per day from the fifth day to the end of the testing period.(for 8 weeks)” NCT04969679 ↗ |